RxDoctor Payments Data

Miran Salgado, MD

Neurology · Brooklyn, NYNPI 1699744268

Payments from drug & device makers

$62,366in general payments, 2019–2025

Across 717 payments — averaging $86.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acorda Therapeutics, Inc$32K
  • Amneal Pharmaceuticals LLC$12K
  • Acadia Pharmaceuticals Inc$5K
  • AbbVie$3K
  • Abbott$3K
  • Teva Pharmaceuticals USA, Inc.$2K
  • plus $5K from 39 others
$19,000in research payments, 2019–2025

Across 4 payments — averaging $4750.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acadia Pharmaceuticals Inc$19K

What the payments were for

  • Consulting fees$1990%
  • Speaking & faculty fees$36,58563%
  • Travel & lodging$6,26911%
  • Food & beverage$14,26325%
  • Education$5501%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$62,366 in reported general payments places this provider in the 80th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$348,709
Medicare patients
620
Services billed
16,808

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4625$218,160
Gamunex-CImmune Globul G/Gly/Iga Avg 4624$166,924
OctagamImmun Globg(Igg)/Malt/Iga Ov5017$162,512
RytaryCarbidopa/Levodopa121$161,473
NeuproRotigotine22$41,569
Rivastigmine153$35,015
Rasagiline Mesylate85$26,950
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone33$8,965
Selegiline Hcl76$6,213
Carbidopa-Levodopa ErCarbidopa/Levodopa94$4,936
Carbidopa-LevodopaCarbidopa/Levodopa111$3,638
Entacapone20$2,618
Pyridostigmine Bromide ErPyridostigmine Bromide11$2,463
Duloxetine Hcl72$2,255
AmantadineAmantadine Hcl34$1,770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$71$166,92424 claims
PfizerOctagam$354$162,51217 claims
Amneal Pharmaceuticals LLCRytary$12,397$161,473121 claims
UCB, Inc.Neupro$113$41,56922 claims
Almatica Pharma LLCSertraline Hcl$24$24933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,623 neurology providers in New York.

Other neurology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →